- Home
- ARVN vs RGNX Comparison
ARVN vs RGNX Comparison
Compare ARVN & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- RGNX
- Stock Information
- Founded
- ARVN 2015
- RGNX 2008
- Country
- ARVN United States
- RGNX United States
- Employees
- ARVN N/A
- RGNX N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARVN Health Care
- RGNX Health Care
- Exchange
- ARVN Nasdaq
- RGNX Nasdaq
- Market Cap
- ARVN 438.1M
- RGNX 387.0M
- IPO Year
- ARVN 2018
- RGNX 2015
- Fundamental
- Price
- ARVN $8.98
- RGNX $8.75
- Analyst Decision
- ARVN Buy
- RGNX Strong Buy
- Analyst Count
- ARVN 15
- RGNX 8
- Target Price
- ARVN $31.86
- RGNX $31.75
- AVG Volume (30 Days)
- ARVN 2.8M
- RGNX 1.0M
- Earning Date
- ARVN 05-06-2025
- RGNX 05-07-2025
- Dividend Yield
- ARVN N/A
- RGNX N/A
- EPS Growth
- ARVN N/A
- RGNX N/A
- EPS
- ARVN N/A
- RGNX N/A
- Revenue
- ARVN $263,399,999.00
- RGNX $83,328,000.00
- Revenue This Year
- ARVN N/A
- RGNX $285.14
- Revenue Next Year
- ARVN N/A
- RGNX N/A
- P/E Ratio
- ARVN N/A
- RGNX N/A
- Revenue Growth
- ARVN 235.54
- RGNX N/A
- 52 Week Low
- ARVN $5.94
- RGNX $5.04
- 52 Week High
- ARVN $37.38
- RGNX $17.99
- Technical
- Relative Strength Index (RSI)
- ARVN 52.04
- RGNX 63.39
- Support Level
- ARVN $5.94
- RGNX $5.85
- Resistance Level
- ARVN $6.86
- RGNX $6.83
- Average True Range (ATR)
- ARVN 0.55
- RGNX 0.66
- MACD
- ARVN 0.58
- RGNX 0.22
- Stochastic Oscillator
- ARVN 93.47
- RGNX 96.43
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.